Epstein-Barr nuclear antigen 1 inhibitor/Latent membrane protein 1 inhibitor (BP InnoMed/Durham University/Chinese University of Hong Kong)

N/A

Report date: 2025/01/26 19:31:15

Base Information

Drug NameEpstein-Barr nuclear antigen 1 inhibitor/Latent membrane protein 1 inhibitor (BP InnoMed/Durham University/Chinese University of Hong Kong)
Drug Alias NameEpstein-Barr nuclear antigen 1 inhibitor (BP InnoMed/Durham University/Chinese University of Hong Kong)anti-EBNA1 viral protein (BP InnoMed)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionEpstein-Barr nuclear antigen 1 inhibitorsLatent membrane protein 1 inhibitors
TargetsEpstein-Barr nuclear antigen 1Latent membrane protein 1
Therapy Area/IndicationsNasopharyngeal CarcinomaNeoplasmsEpstein-Barr Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong Kong
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBP InnoMed Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBP InnoMed LtdChinese University Of Hong Kong (Cuhk)University Of Durham
Inactive CompaniesN/A
Active IndicationsNasopharyngeal CarcinomaEpstein-Barr Virus Infections
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A